The AeriSeal System utilizes a proprietary polymer sealant which is delivered through a bronchoscope reducing lung volume to improve lung function and quality of life in patients.

The expanded EU approval was based on the data from a study in which patients received treatment in two lung regions in each lung during a single bronchoscopic procedure.

Aeris Therapeutics CEO David Dove said with this approval, clinicians are able to treat more damaged lung regions in a single treatment session, which results in better outcomes from a single minimally invasive procedure.

"We can now accelerate our commercialization and scale up of clinical education and training programs and make this therapy available to more patients suffering from emphysema," Dove said.